BIOLASE (NASDAQ:BIOL) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a report released on Wednesday morning. The firm issued a sell rating on the medical technology company’s stock.

A number of other equities analysts also recently commented on the stock. Benchmark reiterated a “speculative buy” rating and issued a $0.40 target price on shares of BIOLASE in a report on Wednesday, October 2nd. Ascendiant Capital Markets reduced their price objective on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd.

BIOLASE Price Performance

BIOLASE stock opened at $0.01 on Wednesday. The firm has a market cap of $167,035.00, a P/E ratio of 0.00 and a beta of 0.67. The business has a fifty day moving average of $0.02 and a two-hundred day moving average of $0.07. BIOLASE has a twelve month low of $0.02 and a twelve month high of $1.94.

Institutional Trading of BIOLASE

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC lifted its stake in shares of BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 143,537 shares of the medical technology company’s stock after buying an additional 131,248 shares during the period. Virtu Financial LLC owned approximately 0.43% of BIOLASE worth $27,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.79% of the company’s stock.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.